These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 24615771)

  • 21. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases.
    Tateishi R; Shiina S; Teratani T; Obi S; Sato S; Koike Y; Fujishima T; Yoshida H; Kawabe T; Omata M
    Cancer; 2005 Mar; 103(6):1201-9. PubMed ID: 15690326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.
    Okuwaki Y; Nakazawa T; Kokubu S; Hidaka H; Tanaka Y; Takada J; Watanabe M; Shibuya A; Minamino T; Saigenji K
    Am J Gastroenterol; 2009 Nov; 104(11):2747-53. PubMed ID: 19603009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.
    Harrison LE; Koneru B; Baramipour P; Fisher A; Barone A; Wilson D; Dela Torre A; Cho KC; Contractor D; Korogodsky M
    J Am Coll Surg; 2003 Nov; 197(5):759-64. PubMed ID: 14585410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective study of a 'popping' sound during percutaneous radiofrequency ablation for hepatocellular carcinoma.
    Fernandes ML; Lin CC; Lin CJ; Chen WT; Lin SM
    J Vasc Interv Radiol; 2010 Feb; 21(2):237-44. PubMed ID: 20031448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma.
    Lee LH; Hwang JI; Cheng YC; Wu CY; Lee SW; Yang SS; Yeh HZ; Chang CS; Lee TY
    PLoS One; 2017; 12(1):e0169655. PubMed ID: 28068369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Radiofrequency of the liver - an update].
    Bangard C
    Rofo; 2011 Aug; 183(8):704-13. PubMed ID: 21318934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience.
    Orlacchio A; Bazzocchi G; Pastorelli D; Bolacchi F; Angelico M; Almerighi C; Masala S; Simonetti G
    Cardiovasc Intervent Radiol; 2008; 31(3):587-94. PubMed ID: 18236104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma.
    Cheung TT; Ng KK; Poon RT; Fan ST
    J Hepatobiliary Pancreat Surg; 2009; 16(5):655-60. PubMed ID: 19370304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computed tomography-guided radiofrequency ablation of hepatocellular carcinoma: treatment efficacy and complications.
    Laspas F; Sotiropoulou E; Mylona S; Manataki A; Tsagouli P; Tsangaridou I; Thanos L
    J Gastrointestin Liver Dis; 2009 Sep; 18(3):323-8. PubMed ID: 19795027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local tumour progression after loco-regional therapy of hepatocellular carcinomas: value of fusion imaging-guided radiofrequency ablation.
    Min JH; Lee MW; Rhim H; Cha DI; Lim S; Choi SY; Lim HK
    Clin Radiol; 2014 Mar; 69(3):286-93. PubMed ID: 24332169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies.
    Frieser M; Kiesel J; Lindner A; Bernatik T; Haensler JM; Janka R; Hahn EG; Strobel D
    Ultraschall Med; 2011 Apr; 32(2):148-53. PubMed ID: 21225567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up.
    Waki K; Aikata H; Katamura Y; Kawaoka T; Takaki S; Hiramatsu A; Takahashi S; Toyota N; Ito K; Chayama K
    J Gastroenterol Hepatol; 2010 Mar; 25(3):597-604. PubMed ID: 20074153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognosis and risk factors for recurrence of small liver cancer after a single session of percutaneous radiofrequency ablation].
    Xia JL; Ye SL; Zou JH; Ren ZG; Gan YH; Wang YH; Chen Y; Ge NL; Tang ZY; Yang BH
    Ai Zheng; 2004 Sep; 23(9):977-80. PubMed ID: 15363186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure?
    Zavaglia C; Corso R; Rampoldi A; Vinci M; Belli LS; Vangeli M; Solcia M; Castoldi C; Prisco C; Vanzulli A; Pinzello G
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):196-201. PubMed ID: 18301300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-session combined therapy with chemoembolization and radiofrequency ablation in hepatocellular carcinoma less than or equal to 5 cm: a preliminary study.
    Kang SG; Yoon CJ; Jeong SH; Kim JW; Lee SH; Lee KH; Kim YH
    J Vasc Interv Radiol; 2009 Dec; 20(12):1570-7. PubMed ID: 19879777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination guidance of contrast-enhanced US and fusion imaging in radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on contrast-enhanced US/fusion imaging.
    Minami T; Minami Y; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Inoue T; Hagiwara S; Ueshima K; Nishida N; Kudo M
    Oncology; 2014; 87 Suppl 1():55-62. PubMed ID: 25427734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.
    Minami Y; Minami T; Hagiwara S; Ida H; Ueshima K; Nishida N; Murakami T; Kudo M
    Eur Radiol; 2018 May; 28(5):1986-1993. PubMed ID: 29196855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients.
    Song YG; Shin SW; Cho SK; Choi D; Rhim H; Lee MW; Kim YS; Park KB; Park HS; Choo SW; Do YS; Choo IW; Hyun D
    Acta Radiol; 2015 Jan; 56(1):70-7. PubMed ID: 24518688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma.
    Numata K; Fukuda H; Morimoto M; Kondo M; Nozaki A; Oshima T; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2012 Oct; 81(10):2746-53. PubMed ID: 22197088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiofrequency ablation of liver metastases-software-assisted evaluation of the ablation zone in MDCT: tumor-free follow-up versus local recurrent disease.
    Keil S; Bruners P; Schiffl K; Sedlmair M; Mühlenbruch G; Günther RW; Das M; Mahnken AH
    Cardiovasc Intervent Radiol; 2010 Apr; 33(2):297-306. PubMed ID: 19688366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.